ImmunityBio, Inc. (IBRX) Stock Analysis — Probabli.AI
AI-powered analysis for IBRX (ImmunityBio, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $6.96 · Market cap: $7.2B · AI outlook: Bullish
ImmunityBio, Inc. showcases outstanding revenue growth, robust development pipelines, and favorable buy-side consensus forecasts. Challenges such as regulatory scrutiny and patent disputes must be monitored closely but do not heavily detract from its long-term bullish outlook. Investors should expect significant price appreciation potential with moderate risk.
Probabilistic 1-Year Outlook
- Bull 48% · Neutral 35% · Bear 17%
- 1-year price estimates — P10: $6 / P50: $10 / P90: $12
- ImmunityBio, Inc. demonstrates strong potential, given its rapid revenue growth estimate, recent positive trial data, and. analyst consensus with a strong buy rating. However, regulatory challenges and recent market…
5-Year Outlook
- Bull 60% · Neutral 25% · Bear 15%
- 5-year price estimates — P10: $8 / P50: $18 / P90: $25
SWOT Highlights
- Strength: Strong revenue growth trajectory.
- Strength: Encouraging trial results for novel therapies.
- Risk: Negative recent price performance and volatility.
- Risk: Regulatory challenges including SEC investigation.
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
7 Wall Street analysts rate IBRX a STRONG BUY with a mean price target of $12.57.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
IBRX forecast details · IBRX sentiment details · IBRX insider activity
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.